Skip to main content

14 Result(s)

within A Marmont Remove this filter

and

  1. Article

    Erratum: Allogeneic hematopoietic SCT for patients with autoimmune diseases

    Correction to: Bone Marrow Transplantation (2009) 44, 27–33; doi:10.1038/bmt.2008.424 Since the publication of their paper, the authors have noticed that one of the co-authors is not listed. C Urban, who is at...

    T Daikeler, T Hügle, D Farge, M Andolina, F Gualandi… in Bone Marrow Transplantation (2009)

    Download PDF (81 KB) View Article

  2. No Access

    Article

    Allogeneic hematopoietic SCT for patients with autoimmune diseases

    Allogeneic hematopoietic SCT (HSCT) has been used as treatment for single patients with autoimmune diseases (AD). To summarise currently available information, we analyzed all patients who underwent allogeneic...

    T Daikeler, T Hügle, D Farge, M Andolina, F Gualandi… in Bone Marrow Transplantation (2009)

  3. No Access

    Article

    Intense immunosuppression followed by autologous stem cell transplantation in severe multiple sclerosis

    Aggressive forms of multiple sclerosis (MS) represent a limited group of demyelinating diseases that rapidly progress to severe disability. Currently available therapies are poorly effective against these clin...

    E. Capello, R. Saccardi, A. Murialdo, F. Gualandi, F. Pagliai… in Neurological Sciences (2005)

  4. No Access

    Article

    Autologous hematopoietic stem cell transplantation for autoimmune diseases

    Experimental data and early phase I/II studies suggest that high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) can arrest progression of severe autoimmune diseases. We...

    A Gratwohl, J Passweg, C Bocelli-Tyndall, A Fassas… in Bone Marrow Transplantation (2005)

  5. Article

    The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis

    Hematopoietic stem cell transplantation (HSCT) is becoming an increasingly recognized indication for treatment of autoimmune diseases and severe immune-mediated disorders. However, multicenter registry data ha...

    R K Burt, K Kallunian, D Patel, J Thomas, A Yeager… in Bone Marrow Transplantation (2004)

    Download PDF (142 KB) View Article

  6. No Access

    Article

    Stem cell therapy for autoimmune disease: overview of concepts from the Snowbird 2002 tolerance and tissue regeneration meeting

    Hematopoietic stem cell transplantation as a treatment for autoimmune disease began in 1996 and has subsequently spread worldwide. In Europe phase III trials have opened, while in America phase III trials are ...

    R K Burt, R Arnold, R Emmons, Y Oyama, A Marmont in Bone Marrow Transplantation (2003)

  7. No Access

    Article

    Development of a phase III trial of hematopoietic stem cell transplantation for systemic lupus erythematosus

    At Northwestern University, a phase I/II trial of hematopoietic stem cell transplant (HSCT) for systemic lupus erythematosus (SLE) has shown promising results. A phase III HSCT trial is being developed to conf...

    R K Burt, A Marmont, R Arnold, F Heipe, G S Firestein… in Bone Marrow Transplantation (2003)

  8. No Access

    Article

    Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favorably affects outcome after stem cell transplantation in human autoimmune diseases

    To determine the role of allogeneic, autologous and syngeneic hemopoietic stem cell transplantation (SCTx) as a treatment for severe autoimmune disease (AID) we performed a literature search employing Medline,...

    W Hinterberger, M Hinterberger-Fischer, A Marmont in Bone Marrow Transplantation (2002)

  9. No Access

    Article

    Hematopoietic stem cell transplantation for multiple sclerosis

    Rationale Phase I/II studies of autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) were initiated, based on results of experimental transplantation in animal mo...

    A.S. Fassas, J. R. Passweg, A. Anagnostopoulos, A. Kazis, T. Kozak… in Journal of Neurology (2002)

  10. No Access

    Article

    Book reviews

    C. Mueller-Eckhardt, A. Marmont in Blut (1987)

  11. No Access

    Chapter

    Bone Marrow Transplantation Versus Chemotherapy for Patients under 15 Years of Age in 2nd Remission Acute Lymphoblastic Leukaemia (ALL)

    Recently the European Bone marrow Transplant Group (EBMT) has reported a significantly different relapse rate for ALL, according whether in first or subsequent remission (1). However, as far as ALL in children...

    F. Frassoni, A. Bacigalupo, M. T. Van Lint, M. Congiu… in 11th Annual meeting of the EBMT (1985)

  12. No Access

    Chapter

    Bone Marrow Transplantation Versus Chemotherapy alone for Acute Nonlymphoblastic Leukemia

    The question whether allogeneic bone marrow transplantation (BMT) carries greater advantage for patients with ANLL as compared to chemotherapy (CT) alone has been and is still debated intensively (1,2). The is...

    A. Marmont, A. Bacigalupo, M. T. Van Lint, F. Frassoni… in 11th Annual meeting of the EBMT (1985)

  13. No Access

    Chapter and Conference Paper

    Ergebnisse der Fluoreszenzzyto- und Histochemie in der Hämatologie

    Obwohl die Fluoreszenzmikroskopie mehr als 5o Jahre alt ist, haben wir in den letzten Jahren eine Renaissance dieses Untersuchungsverfahrens erlebt, das einen integrierenden Bestandteil der sogenannten Neomorp...

    A. Marmont, E. Damasio in Zyto- und Histochemie in der Hämatologie (1963)

  14. No Access

    Chapter and Conference Paper

    Aktuelle Probleme antikörperbedingter hämolytischer Erkrankungen

    Es sind ohne Zweifel die erworbenen hämolytischen Anämien mit inkompletten Wärmeautoantikörpern (I.W.A.) die bedeutendste Kategorie der sogenannten Autoimmunerythropathien. Das erste noch ungelöste sowie prägn...

    A. Marmont in Hämolyse und Hämolytische Erkrankungen (1961)